TriSalus Life Sciences, Inc. (TLSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.00+0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · TLSI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 37.4% |
| Our one-year growth estimate | diamond | 44.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
TLSI — earnings miss
Dated 2026-08-06
Results of Operations and Financial Conditions. On August 6, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…
Why it matters: FDA clearance is key for expanding the PEDD platform and driving revenue growth.
Supportive ifThe FDA has cleared TriNav® Advance. This allows it to reach more markets.
Worry ifNo FDA clearance is granted by the end of Q4 2026, delaying revenue growth.
Why it matters: The revenue guidance shows how well the company is growing. This affects investor trust.
Watch forQ3 revenue guidance is confirmed or raised above $54 million.
Also watch forQ3 revenue guidance is now below $54 million. This shows the company faces challenges.
Why it matters: Good data shows the PEDD platform is valuable. It can bring in more doctors.
Supportive ifThe PEDIR study will share positive clinical data in a well-known journal.
Worry ifThe publication shows bad or unclear results from the PEDIR study.
Why it matters: Higher costs may mean strong efforts to enter the market. But they might also increase losses.
Watch forSales and marketing expenses increase but lead to higher revenue growth above 20% YoY.
Also watch forIf sales and marketing costs go up without revenue growth, it will worsen losses.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$282 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $661 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,640 loss on $10,000 · 66.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New clinical data can help the PEDD platform gain trust and attract more interest.
Supportive ifNew clinical data shows better results with PEDD at big oncology events.
Worry ifNo new important clinical data was presented. This leads to less interest in PEDD.
Why it matters: New evidence can strengthen the case for the PEDD platform and drive adoption.
Watch forNew clinical data shows better outcomes with the PEDD platform.
Also watch forNo new clinical evidence published. This suggests research progress has stopped.
Why it matters: Better operating income shows the company is managing costs well. It means more efficiency.
Supportive ifOperating income gets less negative than -$8 million in Q2 2026.
Worry ifOperating income worsens, going more negative than -$8.41 million in Q2 2026.
Why it matters: Growing losses may show problems with managing costs. This could affect future funding.
Worry ifOperating losses for Q3 2026 are over $10 million.
Less concerning ifOperating losses are under $10 million. This shows better cost management.